Published in
American Society of Hematology, Blood, 4(132), p. 393-404
DOI: 10.1182/blood-2016-09-739086
Links
Tools
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
Journal article published in 2018 by
Jorge E. Cortes,
Dong-Wook Kim,
Javier Pinilla-Ibarz,
Philipp D. le Coutre,
Ronald Paquette,
Charles Chuah,
Franck E. Nicolini,
Jane F. Apperley 
,
H. Jean Khoury,
Moshe Talpaz,
Daniel J. DeAngelo ,
Elisabetta Abruzzese,
Delphine Rea,
Michele Baccarani,
Martin C. Müller
and other authors.
,
H. Jean Khoury,
Moshe Talpaz,
Daniel J. DeAngelo ,
Elisabetta Abruzzese,
Delphine Rea,
Michele Baccarani,
Martin C. Müller
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Ponatinib continued to provide deep, durable responses in heavily pretreated patients with CP-CML. Tolerability was acceptable in this heavily pretreated population with 5 years of follow-up.